Scarica l'app Stockscreener
2.595
3.76%
-0.095
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IOVA Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.69
Aprire:
$2.67
Volume 24 ore:
3.85M
Relative Volume:
0.27
Capitalizzazione di mercato:
$1.03B
Reddito:
$241.53M
Utile/perdita netta:
$-389.92M
Rapporto P/E:
-2.1098
EPS:
-1.23
Flusso di cassa netto:
$-323.54M
1 W Prestazione:
+9.70%
1M Prestazione:
-8.20%
6M Prestazione:
-34.79%
1 anno Prestazione:
-58.18%
Intervallo 1D:
$2.58
$2.69
Intervallo di 1 settimana:
$2.24
$2.72
Portata 52W:
$1.6385
$6.50
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Nome
Iovance Biotherapeutics Inc
Settore
Industria
Telefono
(650) 260-7120
Indirizzo
825 INDUSTRIAL ROAD, SAN CARLOS
Confronta IOVA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.595 | 1.07B | 241.53M | -389.92M | -323.54M | -1.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2025-05-16 | Downgrade | UBS | Buy → Neutral |
| 2025-05-12 | Downgrade | Truist | Buy → Hold |
| 2025-05-09 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-07-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-09-18 | Reiterato | Barclays | Overweight |
| 2023-05-30 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | Ripresa | Wells Fargo | Equal Weight |
| 2023-01-27 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | Downgrade | Goldman | Buy → Neutral |
| 2022-10-31 | Iniziato | Guggenheim | Neutral |
| 2022-08-18 | Ripresa | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Stifel | Hold → Buy |
| 2021-12-07 | Ripresa | Cowen | Outperform |
| 2021-06-10 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | Downgrade | Stifel | Buy → Hold |
| 2021-05-03 | Iniziato | Truist | Buy |
| 2021-04-16 | Iniziato | Goldman | Buy |
| 2021-03-08 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | Iniziato | Mizuho | Buy |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2020-02-26 | Reiterato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-10-01 | Iniziato | Stifel | Buy |
| 2019-04-29 | Iniziato | Piper Jaffray | Overweight |
| 2019-02-28 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-07 | Iniziato | Robert W. Baird | Outperform |
| 2018-12-31 | Ripresa | B. Riley FBR | Buy |
| 2018-07-06 | Reiterato | Chardan Capital Markets | Buy |
| 2018-04-10 | Aggiornamento | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | Reiterato | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | Reiterato | H.C. Wainwright | Buy |
| 2017-11-01 | Reiterato | B. Riley FBR, Inc. | Buy |
Mostra tutto
Iovance Biotherapeutics Inc Borsa (IOVA) Ultime notizie
Advanced Melanoma Pipeline Expands With 60+ Investigational Therapies and 55+ Active Developers, Reports DelveInsight - Barchart.com
Advanced Melanoma Pipeline Expands With 60+ Investigational - openPR.com
Bull Run: Is Iovance Biotherapeutics Inc showing insider buyingEarnings Performance Report & Accurate Technical Buy Alerts - baoquankhu1.vn
Assessing Iovance Biotherapeutics (IOVA) Valuation After Clinical Trial Progress And New FDA Designations - Sahm
What drives Iovance Biotherapeutics Incs stock priceTrade Entry Report & Community Consensus Stock Picks - baoquankhu1.vn
Trend Report: Will TNON benefit from seasonalityPortfolio Gains Summary & Stepwise Trade Execution Plans - baoquankhu1.vn
Dow Update: Can Iovance Biotherapeutics Inc deliver consistent EPS growthPortfolio Performance Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Why Iovance Biotherapeutics Stock Got Mashed on Monday - MSN
Analyst Boosts Iovance’s Price Target Amid Positive Market Moves - timothysykes.com
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Biotech Iovance offers 97,710 stock options to 17 new hires at $2.22 - Stock Titan
Iovance Biotherapeutics Stock Surges Amid Strategic Moves - StocksToTrade
Is Iovance Biotherapeutics (IOVA) A Potential Opportunity After Multi Year Share Price Slide - Sahm
Iovance Biotherapeutics (IOVA) Is Down 14.9% After Governance Scrutiny And Equity Raise Plan Is Revealed - Yahoo Finance
Iovance Biotherapeutics (IOVA) Valuation Check After Amtagvi Outlook Reaffirmation And Governance Concerns - Yahoo Finance
Iovance Biotherapeutics, Inc. (IOVA): A Bull Case Theory - Finviz
Iovance gets conditional Health Canada approval for Amtagvi - MSN
Aug EndMonth: Is Iovance Biotherapeutics Inc still a buy after recent gainsQuarterly Portfolio Review & Daily Growth Stock Tips - baoquankhu1.vn
The Bull Case For Iovance Biotherapeutics (IOVA) Could Change Following Reaffirmed 2025 Guidance And TIL Scale-Up - Sahm
She raised more than $1 billion for Iovance. Now, Maria Fardis has a new startup and a $200 million investment - The Business Journals
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH) - GlobeNewswire
Moving Averages: Is Iovance Biotherapeutics Inc showing insider buying2025 Year in Review & Fast Gaining Stock Reports - baoquankhu1.vn
Published on: 2026-01-12 23:18:26 - Улправда
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Average Rating of "Hold" by Analysts - MarketBeat
Market Moves: How Iovance Biotherapeutics Inc stock performs in weak economyQuarterly Portfolio Report & Weekly Breakout Watchlists - Bộ Nội Vụ
Assessing Iovance Biotherapeutics (IOVA) Valuation After Revenue Guidance And 1,000 Patient Milestone - Sahm
Iovance Highlights Amtagvi Momentum and Confirms 2025 Guidance - The Globe and Mail
Why Iovance Biotherapeutics Inc. stock appeals to dividend seekersWeekly Stock Analysis & Accurate Intraday Trading Signals - Улправда
Iovance Biotherapeutics Inc. (IOVA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Iovance Biotherapeutics, Inc. Updates Corporate Presentation - TradingView — Track All Markets
Why Iovance Biotherapeutics Inc. stock remains resilientJuly 2025 Weekly Recap & Stepwise Swing Trade Plans - ulpravda.ru
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 7.4%What's Next? - MarketBeat
Why retail investors favor Iovance Biotherapeutics Inc. stockStock Price Forecasts & Low Cost Trading Plans - ulpravda.ru
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - MSN
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Down 7.1%Here's What Happened - MarketBeat
Barclays Adjusts Valuation Targets for Iovance Biotherapeutics (IOVA) Amid Biotech Sector Review - Insider Monkey
Barclays adjusts valuation targets for Iovance Biotherapeutics (IOVA) amid biotech sector review - MSN
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street - Finviz
Will Iovance Biotherapeutics Inc. stock attract more institutional investorsCovered Call Writing & Budget Friendly Investment Plans - bollywoodhelpline.com
Iovance Biotherapeutics: Bright Prospects For 2026 (NASDAQ:IOVA) - Seeking Alpha
The next front against cancer: A Mugglehead roundup - Mugglehead Magazine
Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge? - Sahm
Iovance Biotherapeutics (IOVA) Stock News Today: Barclays Raises Target, Short-Interest Pressure, and 2026 Catalysts (Dec. 23, 2025) - ts2.tech
Iovance Biotherapeutics: Is it Time to Invest? - StocksToTrade
Iovance Biotherapeutics (NASDAQ:IOVA) Trading Up 8.7%Still a Buy? - MarketBeat
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(4) - marketscreener.com
Iovance Biotherapeutics Inc Azioni (IOVA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):